Repros Therapeutics announces compliance for continued listing on Nasdaq Capital Market

Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that it believes that it has regained compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market.

As previously announced, for continued listing on the Nasdaq Capital Market, Repros must (i) maintain either stockholders' equity of at least $2.5 million or a market value of listed securities of $35 million pursuant to Listing Rules 5550(b) (1) and (2), respectively, by May 5, 2010 and (ii) maintain a minimum bid price of $1.00 per share pursuant to Listing Rule 5550(a) (2) by June 14, 2010.

As of April 14, 2010, pursuant to the Equity Distribution Agreement dated February 12, 2010 between Repros and Ladenburg Thalman & Co. Inc., Repros believes that it has raised sufficient funds to satisfy the minimum stockholders' equity required for continued listing on the Nasdaq Capital Market.

The Company continues to have until June 14, 2010 to maintain the required minimum bid price for continued listing. During the annual stockholders' meeting to be held on May 17, 2010, the Company's stockholders will vote on a proposal to grant the board of directors the authority to effect a reverse split of its common stock within one year of the annual meeting on a basis not to exceed one share of common stock for up to five shares of common stock outstanding, if necessary, in the sole discretion of the board of directors, for purposes of maintaining the Company's listing on the Nasdaq Capital Market. There can be no assurance that the stockholders will approve this proposal.